Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 1
2006 5
2007 5
2008 3
2009 7
2010 7
2011 10
2012 6
2013 3
2014 12
2015 24
2016 21
2017 30
2018 33
2019 36
2020 44
2021 42
2022 39
2023 49
2024 51
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Results by year

Filters applied: Humans. Clear all
Page 1
The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults.
Aljumaah MR, Bhatia U, Roach J, Gunstad J, Azcarate Peril MA. Aljumaah MR, et al. Clin Nutr. 2022 Nov;41(11):2565-2576. doi: 10.1016/j.clnu.2022.09.012. Epub 2022 Sep 28. Clin Nutr. 2022. PMID: 36228569 Clinical Trial.
BACKGROUND: Advancing age coincides with changes in the gut microbiome and a decline in cognitive ability. Psychobiotics are microbiota-targeted interventions that can result in mental health benefits and protect the aging brain. This study investigated the gut m …
BACKGROUND: Advancing age coincides with changes in the gut microbiome and a decline in cognitive ability. Psychobiotics are micro …
Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis.
Zhao H, Chen X, Zhang L, Meng F, Zhou L, Pang X, Lu Z, Lu Y. Zhao H, et al. Pharmacol Res. 2022 Aug;182:106350. doi: 10.1016/j.phrs.2022.106350. Epub 2022 Jul 14. Pharmacol Res. 2022. PMID: 35843568
In this study, the prevention ability of Lacticaseibacillus rhamnosus Fmb14, screened from Chinese yogurt, was evaluated in chronic purine-induced hyperuricemia (CPH) mice. ...In specific, Fmb14 administration upregulated the diversity of gut microbiota, incr …
In this study, the prevention ability of Lacticaseibacillus rhamnosus Fmb14, screened from Chinese yogurt, was evaluated in ch …
Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial.
Lai H, Li Y, He Y, Chen F, Mi B, Li J, Xie J, Ma G, Yang J, Xu K, Liao X, Yin Y, Liang J, Kong L, Wang X, Li Z, Shen Y, Dang S, Zhang L, Wu Q, Zeng L, Shi L, Zhang X, Tian T, Liu X. Lai H, et al. Gut Microbes. 2023 Jan-Dec;15(1):2197837. doi: 10.1080/19490976.2023.2197837. Gut Microbes. 2023. PMID: 37078654 Free PMC article. Clinical Trial.
Intervention: A: polydextrose; B: psyllium husk; C: wheat bran + psyllium husk; D: Bifidobacterium animalis subsp. lactis HN019 + Lacticaseibacillus rhamnosus HN001; Placebo: maltodextrin. Oligosaccharides were also included in group A to D. 16S rRNA sequencing was …
Intervention: A: polydextrose; B: psyllium husk; C: wheat bran + psyllium husk; D: Bifidobacterium animalis subsp. lactis HN019 + Lactica …
Thirty Years of Lactobacillus rhamnosus GG: A Review.
Capurso L. Capurso L. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. doi: 10.1097/MCG.0000000000001170. J Clin Gastroenterol. 2019. PMID: 30741841 Review.
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. ...
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its abili …
Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
Boggio Marzet C, Burgos F, Del Compare M, Gerold I, Tabacco O, Vinderola G. Boggio Marzet C, et al. Arch Argent Pediatr. 2022 Feb;120(1):e1-e7. doi: 10.5546/aap.2022.eng.e1. Epub 2021 Dec 14. Arch Argent Pediatr. 2022. PMID: 35068121 Free article. Review. English, Spanish.
Our objective was to perform a descriptive review of probiotic use in pediatrics, focused on Lactobacillus rhamnosus GG. Certain probiotics have demonstrated to be effective in acute diarrhea and antibiotic-associated diarrhea. L. rhamnosus GG and Saccharomyces boul …
Our objective was to perform a descriptive review of probiotic use in pediatrics, focused on Lactobacillus rhamnosus GG. Certain prob …
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T, Song Q, Zhu F, Zhang L, Jiang M, Zhou Y, Barve S, Zhang X, McClain CJ, Feng W. Liu Y, et al. Hepatology. 2020 Jun;71(6):2050-2066. doi: 10.1002/hep.30975. Epub 2020 Mar 16. Hepatology. 2020. PMID: 31571251 Free PMC article.
BACKGROUND AND AIMS: Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification of gut microbiota and repression of BA synthesis are potential strategies for the treatment of cholestatic liver disease. ...In addit …
BACKGROUND AND AIMS: Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification …
Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial.
Carucci L, Nocerino R, Paparo L, De Filippis F, Coppola S, Giglio V, Cozzolino T, Valentino V, Sequino G, Bedogni G, Russo R, Ercolini D, Berni Canani R. Carucci L, et al. Pediatr Allergy Immunol. 2022 Aug;33(8):e13836. doi: 10.1111/pai.13836. Pediatr Allergy Immunol. 2022. PMID: 36003050 Free PMC article. Clinical Trial.
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of the pediatric population associated with alteration of skin and gut microbiome. Probiotics have been proposed for AD treatment. The ProPAD study aimed to investigate the therap …
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of the pediatric population associated with al …
Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota in Patients with Lactose Intolerance and Persisting Functional Gastrointestinal Symptoms: A Randomised, Double-Blind, Cross-Over Study.
Vitellio P, Celano G, Bonfrate L, Gobbetti M, Portincasa P, De Angelis M. Vitellio P, et al. Nutrients. 2019 Apr 19;11(4):886. doi: 10.3390/nu11040886. Nutrients. 2019. PMID: 31010241 Free PMC article. Clinical Trial.
We aimed to test the efficacy of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 plus vitamin B6 (ZR) in 23 LI subjects with persistent symptoms during a lactose-free diet. Symptoms, microbiome, and metabolome were measured at b …
We aimed to test the efficacy of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 plus vitamin B …
Lacticaseibacillus rhamnosus GG and Saccharomyces cerevisiae boulardii supplementation exert protective effects on human gut microbiome following antibiotic administration in vitro.
Duysburgh C, Van den Abbeele P, Morera M, Marzorati M. Duysburgh C, et al. Benef Microbes. 2021 Aug 30;12(4):59-73. doi: 10.3920/BM2020.0180. Epub 2021 Jun 30. Benef Microbes. 2021. PMID: 34190033
The impact of repeated administration of Lacticaseibacillus rhamnosus GG (CNCM-I-4798) (formerly known as Lactobacillus rhamnosus GG), Saccharomyces cerevisiae boulardii (CNCM-I-1079) and their combination (associated in Smebiocta/Smectaflora Protect) in supp …
The impact of repeated administration of Lacticaseibacillus rhamnosus GG (CNCM-I-4798) (formerly known as Lactobacillus rha …
Probiotics for induction of remission in Crohn's disease.
Limketkai BN, Akobeng AK, Gordon M, Adepoju AA. Limketkai BN, et al. Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD006634. doi: 10.1002/14651858.CD006634.pub3. Cochrane Database Syst Rev. 2020. PMID: 32678465 Free PMC article.
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, in which the pathogenesis is believed to be partly influenced by the gut microbiome. Probiotics can be used to manipulate the microbiome and have therefore been consid …
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, in which the pathogenesis is believed to …
397 results